Human Acute Myeloid Leukemia PB Plasma (Newly Diagnosed/Untreated)

Description

Human Acute Myeloid Leukemia (AML) PB Plasma (Newly Diagnosed/Untreated) is collected from the peripheral blood of patients at initial AML diagnosis prior to treatment. This plasma contains a rich profile of circulating cytokines, exosomes, and leukemia-derived soluble factors that reflect the systemic disease environment and serve as potential predictive plasma markers AML. It is cell-free and prepared by centrifugation from whole blood under sterile conditions. AML plasma exhibits distinct inflammatory proteomes, including elevated acute-phase proteins and dysregulated lipid metabolism markers. Cytokine and metabolic profiles in AML plasma can be quantified using multiplex bead-based immunoassays or mass spectrometry-based proteomics. Key immune anomalies involve impaired plasmacytoid dendritic cell (pDC) function, contributing to immune evasion. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.